SusanNChiMD

Pediatric Hematology & Oncology • Boston, MA

Pediatric Neuro-Oncology

Assistant Professor of Pediatrics, Dana-Farber Cancer Institute

Join to view full profile

Dr. Chi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Chi's full profile

Already have an account?

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-4386

Fax+1 617-632-4897
Is this information wrong?

Education & Training

NYU Grossman School of MedicineFellowship, Pediatric Neuro-Oncology, 2001 - 2002
New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1998 - 2001
Yale-New Haven Medical CenterChief Residency, Pediatrics, 1997 - 1998
Yale-New Haven Medical CenterResidency, Pediatrics, 1994 - 1997
Icahn School of Medicine at Mount SinaiClass of 1994
Princeton UniversityBA, 1990

Certifications & Licensure

MA State Medical License 2003 - 2025
NH State Medical License 2023 - 2025
CT State Medical License 1997 - 2024
ME State Medical License 2023 - 2024
RI State Medical License 2022 - 2024
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma Start of enrollment: 2018 Sep 24
Terminated
Phase 1, Phase 2
Roles: Contact
Fimepinostat in Treating Brain Tumors in Children and Young Adults Start of enrollment: 2019 Aug 07
Active, not recruiting
Early Phase 1
Roles: Contact, Principal Investigator
Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy Start of enrollment: 2020 Oct 01
Active, not recruiting
Phase 2
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion Start of enrollment: 2021 Apr 08
Recruiting
Early Phase 1
Roles: Contact, Study Chair
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG Start of enrollment: 2022 Jan 10
Recruiting
Phase 1
Roles: Principal Investigator, Contact
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma Start of enrollment: 2023 Apr 10
Recruiting
Phase 2
Roles: Contact
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) Start of enrollment: 2020 Dec 09
Recruiting
Phase 1
Roles: Contact
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas Start of enrollment: 2019 Apr 03
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors Start of enrollment: 2023 Aug 10
Recruiting
Phase 1, Phase 2
Roles: Sponsor-Investigator, Contact, Principal Investigator
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Start of enrollment: 2015 Sep 01
Active, not recruiting
Phase 4
Roles: Contact
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma Start of enrollment: 2022 Dec 16
Recruiting
Phase 2
Roles: Contact
Combination Therapy for the Treatment of Diffuse Midline Gliomas Start of enrollment: 2021 Oct 20
Active, not recruiting
Phase 2
Roles: Contact
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors Start of enrollment: 2022 Nov 21
Recruiting
Phase 1, Phase 2
Roles: Contact
Study of Ribociclib and Everolimus in HGG and DIPG Start of enrollment: 2024 Jan 15
Not yet recruiting
Phase 2
Roles: Contact
Study of Olutasidenib and Temozolomide in HGG Start of enrollment: 2024 Jun 01
Not yet recruiting
Phase 2
Roles: Contact
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults Start of enrollment: 2020 Oct 02
Recruiting
Phase 1
Roles: Contact
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion Start of enrollment: 2024 Sep 01
Not yet recruiting
Early Phase 1
Roles: Contact, Study Chair
Join now to see all

Publications & Presentations

PubMed

Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Lindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, Daniel Landi, Jasper van der Lugt, Sarah E S Leary, Pablo Hernáiz Driever, Simon Bailey, Sébastien Perreau...> ;Nature Medicine. 2024 Mar 11
Cancer survivorship programs at the Dana-Farber Cancer Institute.
Ann H Partridge, Alicia Morgans, Lauren P Knelson, Christopher Recklitis, Larissa Nekhlyudov, Susan N Chi, Lisa B Kenney, Lisa Diller, Lynda M Vrooman> ;Journal of Cancer Survivorship. 2024 Feb 1
5 citations
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Blackman, S. C., Kilburn, L. B., Kilburn, L. B., Lindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, Daniel Landi, Jasper van der Lugt, Sarah E S Leary, Pablo...> ;Nature Medicine. 2024 Jan 1
3 citations
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
Andreas Peyrl, Monika Chocholous, Magnus Sabel, Alvaro Lassaletta, Jaroslav Sterba, Pierre Leblond, Karsten Nysom, Ingrid Torsvik, Susan N Chi, Thomas Perwein, Neil Jo...> ;JAMA Oncology. 2023 Dec 1
3 citations
Current advances in immunotherapy for atypical teratoid rhabdoid tumor (ATRT).
Son Tran, Ashley S Plant-Fox, Susan N Chi, Aru Narendran> ;Neuro-Oncology Practice. 2023 Aug 1
4 citations
A Pilot Study Omitting Radiation in the Treatment of Children with Newly Diagnosed Wnt-Activated Medulloblastoma.
Vasu Munjapara, Dolly Aguilera, Robert C Castellino, Stacie L Stapleton, Daniel Landi, David M Ashley, Cynthia Hawkins, Wendy London, Susan Chi, Pratiti Bandopadhayay,...> ;Clinical Cancer Research. 2023 Dec 15
2 citations
ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma.
Anne-Florence Blandin, Ross Giglio, Maya Srikanth Graham, Guadalupe Garcia, Seth Malinowski, Jared K Woods, Shakti Ramkissoon, Lori Ramkissoon, Frank Dubois, Kathleen ...> ;Clinical Cancer Research. 2023 Jul 14
p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition.
Felix Oppel, Senyao Shao, Sarah Gendreizig, Mark W Zimmerman, Matthias Schürmann, Viyof Ful Flavian, Peter Goon, Susan N Chi, Jon C Aster, Holger Sudhoff, A Thomas Look> ;Molecular Cancer Therapeutics. 2022 Nov 3
1 citations
PD-L1 and PD-1 expression in pediatric central nervous system germ cell tumors.
Jared K Woods, Hart G Lidov, Keith L Ligon, Sandro Santagata, Susan N Chi, Kee Kiat Yeo, Sanda Alexandrescu> ;Modern Pathology. 2022 Dec 1
An international study evaluating the epidemiology of intracranial germ cell tumors in the native versus immigrant Japanese populations: the need for an international ...
Ashley S Plant-Fox, Tomonari Suzuki, Rosdali Y Diaz Coronado, Sidnei Epelman, Luiz Sakamoto, Sylvia Cheng, Takaaki Yanagisawa, Bernard Rosner, Susan N Chi, Mark W Kieran> ;Journal of Neuro-Oncology. 2022 Sep 1
13 citations
Structural variants shape driver combinations and outcomes in pediatric high-grade glioma.
Frank P B Dubois, Ofer Shapira, Noah F Greenwald, Travis Zack, Jeremiah Wala, Jessica W Tsai, Alexander Crane, Audrey Baguette, Djihad Hadjadj, Ashot S Harutyunyan, Ki...> ;Nature Cancer. 2022 Aug 1
Comparison of toxicity following single versus tandem autologous transplant regimens for pediatric medulloblastoma.
Ashley S Plant-Fox, Clement Ma, Hasan Al-Sayegh, Derek Shyr, Michelle A Lee, Leslie E Lehmann, Susan N Chi> ;Pediatric Transplantation. 2022 Jun 1
2 citations
DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis.
Kevin X Liu, Helen H Shang, Emily Everdell, Ayal A Aizer, Rifaquat Rahman, Seth Malinowski, David M Meredith, Junne Kamihara, Patrick Y Wen, Keith L Ligon, Susan N Chi...> ;Journal of Neuro-Oncology. 2022 May 1
Pearls & Oy-sters: Pivoting Treatment Regimens of Pediatric Atypical Teratoid Rhabdoid Tumors to Optimize Care in Adult ATRT: A Case Report.
Rohan Rao, Abigail Koehler, Yehudit Rothman, Brandi Turner, Jamie Denlinger, Melissa Erickson, Matthew Hagen, Timothy S Braverman, Abdelkader Mahammedi, Karl Golnik, M...> ;Neurology. 2022 Apr 26
13 citations
Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma.
Tom Rosenberg, Kee Kiat Yeo, Audrey Mauguen, Sanda Alexandrescu, Sanjay P Prabhu, Jessica W Tsai, Seth Malinowski, Mrinal Joshirao, Karishma Parikh, Sameer Farouk Sait...> ;Neuro-Oncology. 2022 Nov 2
1 citations
The challenges in treating Embryonal Tumors with Multilayered Rosettes (ETMR) and other infant brain tumors.
Pratiti Bandopadhayay, Susan N. Chi> ;Neuro-Oncology. 2021 Sep 3
21 citations
Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening...
Adam S. Levy, Mark Krailo, Susan N. Chi, Doojduen Villaluna, Linda Springer, Chris Williams-Hughes, Maryam Fouladi, Amar Gajjar> ;Pediatric Blood & Cancer. 2021 Apr 12
6 citations
Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology
David S. Shulman, Lulla V Kiwinda, Stacey Edwards, Catherine Clinton, Sarah K. Hunt, Lianne Greenspan, Kristen Lawler, Gregory H. Reaman, Hasan Al-Sayegh, Kira Bona, A...> ;Cancer Medicine. 2021 Mar 9
5 citations
Outcomes after first relapse of childhood intracranial ependymoma.
Jessica W Tsai, Neevika Manoharan, Sanda Alexandrescu, Mary Ann Zimmerman, Jacqueline Scully, Christine Chordas, Jessica Clymer, Karen Wright, Mariella G. Filbin, Nico...> ;Pediatric Blood & Cancer. 2021 Feb 9
15 citations
A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma
Karen Wright, Xiaopan Yao, Wendy B. London, Pei Chi Kao, Lia Gore, Stephen P. Hunger, Russ Geyer, Kenneth J. Cohen, Jeffrey C. Allen, Howard M. Katzenstein, Amy Smith,...> ;Pediatric Blood & Cancer. 2021 Feb 1
57 citations
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma
Sabine Mueller, Jared Taitt, Javier Villanueva-Meyer, Erin R Bonner, Takahide Nejo, Rishi Lulla, Stewart Goldman, Anu Banerjee, Susan N. Chi, Nicholas S Whipple, John ...> ;The Journal of Clinical Investigation. 2020 Dec 1
38 citations
A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a...
Nicole J. Ullrich, Sanjay P. Prabhu, Alyssa Reddy, Michael Fisher, Roger J. Packer, Stewart Goldman, Nathan Robison, David H. Gutmann, David Viskochil, Jeffrey C. Alle...> ;Neuro-Oncology. 2020 Oct 14
35 citations
Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma
Neevika Manoharan, Jungwhan John Choi, Christine Chordas, Mary Ann Zimmerman, Jacqueline Scully, Jessica Clymer, Mariella G. Filbin, Nicole J. Ullrich, Pratiti Bandopa...> ;Journal of Neuro-Oncology. 2020 Aug 11
19 citations
Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors.
Lindsey Hoffman, Elizabeth Anne Richardson, Ben Ho, Ashley Margol, Alyssa Reddy, Lucie Lafay-Cousin, Susan N. Chi, Irene Slavc, Alexander R. Judkins, Martin Hasselblat...> ;Neuro-Oncology. 2020 Jul 7
35 citations
Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience.
Jungwhan Choi Choi, Sanda Alexandrescu, Mary Ann Zimmerman, Tabitha Cooney, Christine Chordas, Jessica Clymer, Susan N. Chi, Kee Kiat Yeo> ;Journal of Neuro-Oncology. 2020 Jul 5
Join now to see all

Press Mentions

EZH2 Inhibitor Shows Promise Among Children with Certain Solid TumorsFebruary 20th, 2018
What ‘Beans’ Taught Her Parents About Pediatric Cancer, the Need for Research, and Patient AdvocacyMarch 23rd, 2021